
Surgalign Holdings SRGA
Quarterly report 2023-Q1
added 05-11-2023
Surgalign Holdings Book Value 2011-2026 | SRGA
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Surgalign Holdings
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -15.7 M | 18.2 M | 24.2 M | 34.6 M | 184 M | 182 M | 165 M | 181 M | 168 M | 168 M | 184 M | 172 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 184 M | -15.7 M | 122 M |
Quarterly Book Value Surgalign Holdings
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.93 M | -15.7 M | 22.4 M | 30.8 M | 35.7 M | 18.2 M | 47.1 M | 52.8 M | 46.4 M | 24.2 M | 24.2 M | 24.2 M | 24.2 M | 101 M | 101 M | 101 M | 101 M | 248 M | 250 M | 250 M | 250 M | 245 M | 246 M | 226 M | 223 M | 224 M | 236 M | 238 M | 239 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 250 M | -15.7 M | 124 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
3.85 B | $ 175.92 | 0.8 % | $ 13.2 B | ||
|
Bio-Rad Laboratories
BIO
|
6.57 B | $ 278.4 | 0.33 % | $ 7.85 B | ||
|
Alphatec Holdings
ATEC
|
791 M | $ 11.19 | 1.08 % | $ 1.68 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
1.53 B | $ 12.28 | 0.49 % | $ 1.66 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.62 | 2.5 % | $ 38.6 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
1.82 B | $ 38.29 | 0.82 % | $ 5.7 K | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 61.36 | 0.16 % | $ 90.8 B | ||
|
EDAP TMS S.A.
EDAP
|
56.9 M | $ 3.37 | 0.3 % | $ 126 M | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
ClearPoint Neuro
CLPT
|
28 M | $ 8.81 | -1.67 % | $ 249 M | ||
|
Electromed
ELMD
|
43.2 M | $ 24.41 | - | $ 206 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
Helius Medical Technologies
HSDT
|
2.35 M | $ 1.88 | -0.68 % | $ 1.14 M | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
Globus Medical
GMED
|
4.57 B | $ 91.28 | -0.13 % | $ 12.3 B | ||
|
Butterfly Network
BFLY
|
169 M | $ 4.16 | 0.36 % | $ 881 M | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
IRIDEX Corporation
IRIX
|
4.92 M | $ 1.02 | -1.92 % | $ 17.3 M | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
111 M | $ 9.9 | 0.2 % | $ 355 M | ||
|
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | ||
|
Inogen
INGN
|
192 M | $ 6.73 | 0.98 % | $ 179 M | ||
|
Inspire Medical Systems
INSP
|
781 M | $ 56.97 | 0.41 % | $ 1.67 B | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 36.97 | -0.05 % | $ 1.15 B | ||
|
Integer Holdings Corporation
ITGR
|
1.75 B | $ 87.0 | 0.28 % | $ 3.02 B | ||
|
FONAR Corporation
FONR
|
146 M | $ 18.6 | -0.05 % | $ 122 M | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
10.3 B | $ 78.89 | -0.32 % | $ 46.1 B | ||
|
LivaNova PLC
LIVN
|
1.2 B | $ 63.94 | 0.9 % | $ 3.49 B | ||
|
LENSAR
LNSR
|
-12.2 M | $ 5.46 | - | $ 65.3 M | ||
|
OrthoPediatrics Corp.
KIDS
|
347 M | $ 16.12 | 1.13 % | $ 378 M | ||
|
Myomo
MYO
|
11.4 M | $ 0.69 | -1.17 % | $ 28.9 M |